173 related articles for article (PubMed ID: 7511294)
1. [Uroplakin III, a specific membrane protein of urothelial umbrella cells, as a histological markers for metastatic transitional cell carcinomas].
Moll R; Laufer J; Wu XR; Sun TT
Verh Dtsch Ges Pathol; 1993; 77():260-5. PubMed ID: 7511294
[TBL] [Abstract][Full Text] [Related]
2. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas.
Moll R; Wu XR; Lin JH; Sun TT
Am J Pathol; 1995 Nov; 147(5):1383-97. PubMed ID: 7485401
[TBL] [Abstract][Full Text] [Related]
3. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas.
Kaufmann O; Volmerig J; Dietel M
Am J Clin Pathol; 2000 May; 113(5):683-7. PubMed ID: 10800401
[TBL] [Abstract][Full Text] [Related]
4. [Non-urothelial tumors of the urinary tract].
Mikuz G
Verh Dtsch Ges Pathol; 1993; 77():180-98. PubMed ID: 7511278
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors.
Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC
Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713
[TBL] [Abstract][Full Text] [Related]
6. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture.
Cox RM; Schneider AG; Sangoi AR; Clingan WJ; Gokden N; McKenney JK
Am J Surg Pathol; 2009 Aug; 33(8):1213-9. PubMed ID: 19542871
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
Feil G; Maurer S; Nagele U; Krug J; Bock C; Sievert KD; Stenzl A
Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
[TBL] [Abstract][Full Text] [Related]
8. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
9. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
10. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
[TBL] [Abstract][Full Text] [Related]
11. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines.
Moll R; Achtstätter T; Becht E; Balcarova-Ständer J; Ittensohn M; Franke WW
Am J Pathol; 1988 Jul; 132(1):123-44. PubMed ID: 2456018
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
14. Differential immunocytochemical staining patterns of uroplakin observed on neoplastic and nonneoplastic tissue fragments obtained from upper urinary tract brush specimens.
Xu X; Genega EM; Nasuti JF
Acta Cytol; 2002; 46(4):684-9. PubMed ID: 12146031
[TBL] [Abstract][Full Text] [Related]
15. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
Esheba GE; Longacre TA; Atkins KA; Higgins JP
Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
[TBL] [Abstract][Full Text] [Related]
16. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
17. Transitional cell carcinoma of the upper urinary tract: analysis of morphology and distribution for surgical management.
Fujimoto H; Tobisu K; Mizutani T; Sakamoto M; Kakizoe T
Jpn J Clin Oncol; 1993 Oct; 23(5):303-8. PubMed ID: 8230755
[TBL] [Abstract][Full Text] [Related]
18. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.
Olsburgh J; Harnden P; Weeks R; Smith B; Joyce A; Hall G; Poulsom R; Selby P; Southgate J
J Pathol; 2003 Jan; 199(1):41-9. PubMed ID: 12474225
[TBL] [Abstract][Full Text] [Related]
19. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins.
Riedel I; Czernobilsky B; Lifschitz-Mercer B; Roth LM; Wu XR; Sun TT; Moll R
Virchows Arch; 2001 Feb; 438(2):181-91. PubMed ID: 11253121
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
